The bioweapons cartel (3)

By: James V. Kohl | Published on: April 17, 2024

If you have not linked Transcriptional regulation and post-translational modifications in the glycolytic pathway for targeted cancer therapy 4/15/24 to constraints on all virus-driven pathology across kingdoms, see SARS-CoV-2 spike S2 subunit inhibits p53 activation of p21(WAF1), TRAIL Death Receptor DR5 and MDM2 proteins in cancer cells 4/15/24

SARS-CoV-2 spike S2 subunit inhibits p53 activation…” is in the top 5% of all research outputs scored by Altmetric.

It links energy as information at the origin of life to biophysically constrained protein folding chemistry and all pH-dependent biodiversity on Earth via 20 copies of p53 in cancer-free African elephants.

For comparison, the bioweapons cartel is involved in 5th Generation Warfare (censorship), which appears to prevent others from linking the claims from RFK Jr,’s The Wuhan Cover-Up: And the Terrifying Bioweapons Arms Race” to Michael Nehls The Indoctrinated Brain: How to Successfully Fend Off the Global Attack on Your Mental Freedom via my group’s claims in Human pheromones: integrating neuroendocrinology and ethology 10/22/01

Historical perspective:

In 1995, I gave Eugene Garfield a copy of The Scent of Eros: Mysteries of Odor in Human Sexuality (1995/2002), and he gave me a free life-time subscription to “The Scientist.” The issue on “Making Sense of Smell” was published in October 2013, after I published Nutrient-dependent/pheromone-controlled adaptive evolution: a model

This 10-min read links Demongeot & Henrion-Caude’s 4/25/20 claims in Footprints of a Singular 22-Nucleotide RNA Ring at the Origin of Life to ATP-dependent peptide synthesis at the origin of life to all biodiversity on Earth via biophysically constrained pheromone-regulated epigenetic effects on regulatory T cells and viral latency (aka RNA interference/RNAi) across kingdoms during the past 6-10K years of ecological adaptations.

See: Next-generation CAR and TCR Cancer Therapies 3/15/24

References

  1. Rosenberg SA, et al. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science. 1986;233(4770):1318-1321. 
  2. Rosenberg SA, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N Engl J Med. 1988;319:1676-1680.
  3. Irvine DJ, et al. The future of engineered immune cell therapies. Science. 2022;378(6622):853-858.
  4. Klebanoff CA, et al. T cell receptor therapeutics: Immunological targeting of the intracellular cancer proteome. Nat Rev Drug Discov. 2023;22:996-1017.
  5. Levin AG, et al. CAR T cells: Building on the CD19 paradigm. Eur J Immunol. 2021;51(9):2151-2163.
  6. Eshhar Z, et al. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci USA. 1993;90(2):720-724.
  7. Maher J, et al. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ/CD28 receptor. Nat Biotechnol. 2002;20(1):70-75.
  8. Rafiq S, et al. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat Rev Clin Oncol. 2019;17(3):147-167.
  9. Trinchieri G. Interleukin-12: A cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood. 1994;84(12):4008-4027.
  10. Leonard JP, et al. Effects of a single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-???? production. Blood. 1997;90(7):2541-2548.
  11. Yeku OO, et al. Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment. Sci Rep. 2017;7(1):10541.
  12. Pegram HJ, et al. Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood. 2012;119(18):4133-4141.
  13. Jan M, et al. Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide. Sci Transl Med. 2021;13(575):eabb6295.
  14. Wu C-Y, et al. Remote control of therapeutic T cells through a small molecule-gated chimeric receptor. Science. 2015;350(6258):eaab4077.
  15. Juillerat A, et al. Modulation of chimeric antigen receptor surface expression by a small molecule switch. BMC Biotechnol. 2019;19:44.
  16. Allen GM, Lim WA. Rethinking cancer targeting strategies in the era of smart cell therapeutics. Nat Rev Cancer. 2022;22(12):693-702.
  17. Wilkie S, et al. Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling. J Clin Immunol. 2012;32(5):1059-1070.
  18. Kloss CC, et al. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat Biotechnol. 2013;31(1):71-75.
  19. Morsut L, et al. Engineering customized cell sensing and response behaviors using synthetic notch receptors. Cell. 2016;164(4):780-791.
  20. Roybal KT, et al. Precision tumor recognition by T cells with combinatorial antigen-sensing circuits. Cell. 2016;164(4):770-779.
  21. Williams JZ, et al. Precise T cell recognition programs designed by transcriptionally linking multiple receptors. Science. 2020;370(6520):1099-1104.
  22. Allen GM, et al. Synthetic cytokine circuits that drive T cells into immune-excluded tumors. Science. 2022;378(6625):eaba1624.
  23. Hernández-López RA, et al. T cell circuits that sense antigen density with an ultrasensitive threshold. Science. 2021;371(6534):1166-1171.
  24. Thul PJ, et al. A subcellular map of the human proteome. Science. 2017;356(6340):eaal3321.
  25. Kawakami Y, et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA. 1994;91(9):3515-3519.
  26. Clay TM, et al. Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. J Immunol. 1999;163(1):507-513.
  27. Ellis JM, et al. Frequencies of HLA-A2 alleles in five US population groups: Predominance of A*02011 and identification of HLA-A*0231. Human Immunol. 2000;61(3):334-340.
  28. Drexler HG, et al. Incidence of TdT positivity in cases of leukemia and lymphoma. Acta Haematol. 1986;75(1):12-17.
  29. Kumari S, et al. Alloreactive cytotoxic T cells provide means to decipher the immunopeptidome and reveal a plethora of tumor-associated self-epitopes. Proc Natl Acad Sci USA. 2013;111(1):403-408.
  30. Ali M, et al. T cells targeted to TdT kill leukemic lymphoblasts while sparing normal lymphocytes. Nat Biotechnol. 2021;40:488-498.
  31. Nathan P, et al. Overall survival benefit with tebentafusp in metastatic uveal melanoma. N Engl J Med. 2021;385:1196-1206.
  32. Liddy N, et al. Monoclonal TCR-redirected tumor cell killing. Nat Med. 2012;18:980-987.
  33. Dao T, et al. Therapeutic bispecific T cell engager antibody targeting the intracellular oncoprotein WT1. Nat Biotechnol. 2015;33:1079-1086.
  34. Helsen CW, et al. The chimeric TAC receptor co-opts the T cell receptor yielding robust anti-tumor activity without toxicity. Nat Commun. 2018;9:3049.
  35. Baeurele PA, et al. Synthetic TRuC receptors engaging the complete T cell receptor for potent anti-tumor response. Nat Commun. 2019;10:2087.
  36. Purbhoo MA, et al. T cell killing does not require the formation of a stable mature immunological synapse. Nat Immunol. 2004;5:524-530.
  37. Liu Y, et al. Chimeric STAR receptors using TCR machinery mediate robust responses against solid tumors. Sci Transl Med. 2021;13(586):eabb5191.
  38. Mansilla-Soto J, et al. HLA-independent T cell receptos for targeting tumors with low antigen density. Nat Med. 2022;28:345-352.
  39. Baulu E, et al. TCR-engineered T cell therapy in solid tumors: State of the art and perspectives. Sci Adv. 2023;9(7):eadf3700.
  40. Hong DS, et al. Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: A phase I trial. Nat Med. 2023;29:104-114.


Subscribe
Notify of
guest
0 Comments
Oldest
Newest Most Voted
Inline Feedbacks
View all comments

[…] From The bioweapons (3) […]


Want more on the same topic?

Swipe/Drag Left and Right To Browse Related Posts: